Center-Authored Papers

Filters: Author is Hendrie, Paul C  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
W
Walter RB, Medeiros BC, Gardner KM, Orlowski KF, Gallegos L, Scott BL, Hendrie PC, Estey EH.  2013.  Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase 1/2 study.. Haematologica. Abstract
V
Vaughn JE, Othus M, Powell MA, Gardner KM, Rizzuto DL, Hendrie PC, Becker PS, Pottinger PS, Estey EH, Walter RB.  2015.  Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.. JAMA oncology. :1-8. Abstract
T
Tong W-G, Sandhu VK, Wood BL, Hendrie PC, Becker PS, Pagel JM, Walter RB, Estey EH.  2015.  Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia.. Haematologica. 100(3):e97-8.
S
Shadman M, Mawad R, Dean C, Chen TL, Shannon-Dorcy K, Sandhu V, Hendrie PC, Scott BL, Walter RB, Becker PS et al..  2015.  Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.. American journal of hematology. 90(6):483-6. Abstract
O
Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM et al..  2013.  A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.. British journal of haematology. 163(1):130-2.
M
Martin DB, Silas S, Covner A, Hendrie PC, Stewart FM.  2015.  Development of a Hematology/Oncology ICD-10 Documentation Job Aid.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(4):435-40. Abstract
L
Lionberger JM, Pagel JM, Sandhu VK, Xie H, Shadman M, Mawad R, Boehm A, Dean C, Shannon-Dorcy K, Scott BL et al..  2014.  Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design.. British journal of haematology. 166(3):375-81. Abstract
F
Floeter AE, Patel A, Tran M, Chamberlain MC, Hendrie PC, Gopal AK, Cassaday RD.  2017.  Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.. Clinical lymphoma, myeloma & leukemia. Abstract
C
Chen X, Othus M, Wood BL, Walter RB, Percival M-EM, Becker PS, Hendrie PC, Appelbaum FR, Estey EH.  2017.  Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.. Leukemia & lymphoma. :1-3.
B
Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer BE, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR et al..  2011.  Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.. British journal of haematology. 155(2):182-9. Abstract
Becker PS, Medeiros BC, Stein AS, Othus M, Appelbaum FR, Forman SJ, Scott BL, Hendrie PC, Gardner KM, Pagel JM et al..  2015.  G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.. American journal of hematology. 90(4):295-300. Abstract